385 related articles for article (PubMed ID: 35915225)
1. Circulating tumour DNA - looking beyond the blood.
Tivey A; Church M; Rothwell D; Dive C; Cook N
Nat Rev Clin Oncol; 2022 Sep; 19(9):600-612. PubMed ID: 35915225
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
[TBL] [Abstract][Full Text] [Related]
3. The value of cell-free DNA for molecular pathology.
Stewart CM; Kothari PD; Mouliere F; Mair R; Somnay S; Benayed R; Zehir A; Weigelt B; Dawson SJ; Arcila ME; Berger MF; Tsui DW
J Pathol; 2018 Apr; 244(5):616-627. PubMed ID: 29380875
[TBL] [Abstract][Full Text] [Related]
4. Liquid-based biomarkers in breast cancer: looking beyond the blood.
Shuai Y; Ma Z; Ju J; Wei T; Gao S; Kang Y; Yang Z; Wang X; Yue J; Yuan P
J Transl Med; 2023 Nov; 21(1):809. PubMed ID: 37957623
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
Ranghiero A; Frascarelli C; Cursano G; Pescia C; Ivanova M; Vacirca D; Rappa A; Taormina SV; Barberis M; Fusco N; Rocco EG; Venetis K
Cytopathology; 2023 Nov; 34(6):519-529. PubMed ID: 37640801
[TBL] [Abstract][Full Text] [Related]
6. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
7. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
10. Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.
Rodda AE; Parker BJ; Spencer A; Corrie SR
ACS Sens; 2018 Mar; 3(3):540-560. PubMed ID: 29441780
[TBL] [Abstract][Full Text] [Related]
11. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies.
Escudero L; Martínez-Ricarte F; Seoane J
Curr Opin Neurol; 2020 Dec; 33(6):736-741. PubMed ID: 33177377
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy of circulating tumor DNA and biosensor applications.
Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
[TBL] [Abstract][Full Text] [Related]
17. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
18. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
20. The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
Davidson BA; Croessmann S; Park BH
Br J Cancer; 2021 Sep; 125(6):780-788. PubMed ID: 34040179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
